ADVAGEN, a Singapore based company founded in 2006 which develops and markets healthcare supplements and pharmaceuticals, is pleased to announce its chemotherapeutic product, Docetaxel ADVAGEN, is now approved in Singapore.

“We are happy to have Docetaxel ADVAGEN registered and approved in Singapore. We hope to make the product available to doctors and patients at the earliest,” said Koh of ADVAGEN. “This will provide the doctors and patients with a safe, effective and also a more affordable treatment option.”